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It is widely recognized that mitochondrial dysfunction, most notably defects in the NADH-quinone oxidoreductase (complex I),
is closely related to the etiology of sporadic Parkinson’s disease (PD). In fact, rotenone, a complex I inhibitor, has been used for
establishing PD models both in vitro and in vivo. A rat model with chronic rotenone exposure seems to reproduce
pathophysiological conditions of PD more closely than acute mouse models as manifested by neuronal cell death in the
substantia nigra and Lewy body-like cytosolic aggregations. Using the rotenone rat model, we investigated the protective
effects of alternative NADH dehydrogenase (Ndi1) which we previously demonstrated to act as a replacement for complex I
both in vitro and in vivo. A single, unilateral injection of recombinant adeno-associated virus carrying the NDI1 gene into the
vicinity of the substantia nigra resulted in expression of the Ndi1 protein in the entire substantia nigra of that side. It was clear
that the introduction of the Ndi1 protein in the substantia nigra rendered resistance to the deleterious effects caused by
rotenone exposure as assessed by the levels of tyrosine hydroxylase and dopamine. The presence of the Ndi1 protein also
prevented cell death and oxidative damage to DNA in dopaminergic neurons observed in rotenone-treated rats. Unilateral
protection also led to uni-directional rotation of the rotenone-exposed rats in the behavioral test. The present study shows, for
the first time, the powerful neuroprotective effect offered by the Ndi1 enzyme in a rotenone rat model of PD.
Citation: Marella M, Seo BB, Nakamaru-Ogiso E, Greenamyre JT, Matsuno-Yagi A, et al (2008) Protection by the NDI1 Gene against Neurodegeneration
in a Rotenone Rat Model of Parkinson’s Disease. PLoS ONE 3(1): e1433. doi:10.1371/journal.pone.0001433
INTRODUCTION
Parkinson’s disease (PD) is one of the most common neurodegen-
erative disorders affecting people over 60 years old [1]. The most
notable pathological aspect of PD is the loss of the nigrostriatal
pathway and, more precisely, of the dopaminergic neurons in the
substantia nigra (SN). It should be noted that more than 95% of
PD is sporadic but not autosomal. Attempts have been made to
develop therapies for a number of targets such as monoamine
oxidase B, dopamine level, growth factors, oxidative stress and
apoptosis. Unfortunately, these agents are known to be only
moderately effective for PD [2–5]. Therefore, it is important to
develop new therapies for PD on the basis of innovative concepts.
Recently, it has been reported that sporadic PD is associated
with dysfunction of mitochondria, particularly that of the proton-
translocating NADH-quinone oxidoreductase (complex I) [6,7]. In
fact, it is known that many patients of PD have decreased complex
I activity [7,8]. Furthermore, complex I inhibitors such as 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone
and acetogenins have been demonstrated to induce Parkinsonian
symptoms in animals [9–11].
The alternative NADH-quinone oxidoreductase of Saccharomyces
cerevisiae mitochondria (Ndi1) is composed of a single polypeptide
which is encoded by the NDI1 gene, and is insensitive to complex I
inhibitors [12,13]. Therefore, we advocated that yeast Ndi1
protein may be useful to protect against the symptoms of PD. So
far the Ndi1 protein can be functionally expressed in rodent
systems both in vitro and in vivo [14–16]. In addition, we
demonstrated that Ndi1 protein has protective effects against
inhibition of NADH oxidase activity by complex I inhibitors and
overproduction of ROS caused by complex I defects in vitro [17].
We showed that the Ndi1 protein protected against neurodegen-
eration and behavioral deficits of acute MPTP mouse model of PD
[18,19]. More recently, rotenone rat models of PD have been
developed that reproduce many biochemical and behavioral
characteristics observed in human PD such as irreversible cell
death of dopamine neurons and formation of Lewy body-like
cytoplasmic inclusions [20–22]. In order to evaluate the Ndi1
protein as a potential therapeutic agent for PD, it is a prerequisite
to investigate whether the Ndi1 protein is capable of protecting the
nigrostriatal system against Parkinsonian symptoms in rotenone
rat models of PD. In this paper, we present the results in support of
great potential of the Ndi1 protein as an agent to retard PD.
Experimental Procedure
Animals and experimental design Forty two 5-month-old male
Sprague-Dawley rats were used for this study. All animals were given
standard rat chow and water ad-libitum. The rat’s weight was
approximately 480–520 g at the time of surgery. Animals were first
divided in 2 groups: one group received unilateral intracerebral
injection of recombinant adeno-associated virus (AAV) harboring
the NDI1 gene (serotype 5; Applied Viromics) and the other group
received intracerebral PBS injection. Then, each group was further
divided into 2 groups: one group received subcutaneous injection of
rotenone microspheres and the other received subcutaneous
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injection of the same amount of PBS microspheres. The four groups
were labeled as ‘‘NDI1’’ (NDI1 injection into the right SN and
subcutaneous injection of PBS, this group was composed of 5
animals), ‘‘NDI1+rotenone’’ (NDI1 injection into the right SN and
subcutaneous injection of rotenone, this group was composed of 20
animals), ‘‘control’’ (PBS injection into the right SN and
subcutaneous injection of PBS, this group was composed of 3
animals) and ‘‘control+rotenone’’ (PBS injection into the right SN
and subcutaneous injection of rotenone, this group was composed of
14 animals). The quantity of microspheres injected was adjusted in
such a way that each rat receives 100 mg of rotenone per kg of body
weight. The microspheres were assumed to incorporate 100% of
rotenone used for the preparation. Subcutaneous injections of
microspheres were performed 45 days after virus injections to allow
a complete expression of the Ndi1 protein in the brain. Thirty days
after the microsphere injection, the first round of behavioral tests
were carried out and brain samples were collected from some of the
animals. Half of the samples were used for immunohistochemistry
and the other half for chemical determination of dopamine and its
metabolites. After another 30 days the remaining animals were
tested exactly in the same way.
Surgery Three-ml of AAV serotype 5 carrying the NDI1 gene
(3.161012 genome copy/ml) or 3 ml of PBS were injected intra-
cerebrally at 240 nl/min into the SN of the rats as previously
described [16]. The injection target had the following stereotaxic
coordinates: antero-posterior from the bregma, -5.3 mm; media-
lateral from the bregma, -2.4 mm; dorso-ventral from the dural
surface, 7 mm.
Preparation of microspheres Biodegradable polymer of
poly(DL-lactide-co-glycolide) (PLGA; lactide:glycolide 75:25, mol.
wt. 90,000–126,000, Sigma) containing rotenone were prepared
according to an emulsion solvent evaporation/extraction method.
Rotenone (75 mg) and PLGA (400 mg) were dissolved in 15 ml of
dichloromethane. The solution was vortexed for at least 15 min at
ambient temperature. The organic phase was poured into ice-cold
4% (w/v) polyvinyl alcohol (hot water soluble; Sigma). The emulsion
was stirred at maximum speed for 1 hour in hermetic condition.
Then the seal was broken in order to evaporate the dichloromethane
for 4 hours at ambient temperature. The microspheres were
collected by centrifugation, washed with distilled water, dried, and
kept at 220uC until use. For controls, rotenone was replaced with
PBS. The average diameter of the beads was estimated to be 50 mm.
Histological analysis Brain samples were collected after
perfusion with 4% paraformaldehyde (v/w, pH 7.4) and were
placed in 4% paraformaldehyde for 2 hours at 4uC and in 20%
sucrose (v/w, pH 7.4) overnight. Coronal sections of 30 mm were
collected onto superfrost slide (Fisher) and stored at 220uC. 7,8-
dihydro-8-oxo-deoxyguanine (8-oxo-dG) staining was performed
as previously described [23]. Briefly, brain slices were incubated in
70% ethanol precooled to 220uC for 10 minutes on ice. After
rinsing with PBS the slides were soaked in 37uC PBS
supplemented with 100 mg/mL RNase A, DNase-free for 1 hr.
Staining was enhanced by incubation of the slices with 4 N HCl
for 7 minutes followed by neutralization with two 2-minutes
washes with 500 mM Tris-HCl, pH 7.4. Blocking for immuno-
staining was done in TBS containing 5% FBS, 5% horse serum
and 0.05% Triton-X-100 for 2 hr. The slides were incubated with
primary mouse anti-8-oxo-dG antibody (1/300) in TBS containing
2.5% FBS, 2.5% horse serum and 0.05% Triton-X-100 overnight
at 4uC and then with FITC-labeled anti-mouse secondary
antibody (1/100) in the same medium for 5 hr at room
temperature. Alpha-synuclein and ubiquitin staining were
performed with specific antibodies diluted at 1/300 in PBS,
10% horse serum and 0.1% triton X-100. Both antibodies were
revealed with a biotinylated secondary antibody and the ABC Elite
kit (Vector Laboratories). For the Ndi1 protein and tyrosine
hydroxylase (TH) revelation using fluorescence, brain slices were
boiled twice for 5 min in 10 mM Tris-Cl, pH 10, washed with
PBS, and blocked using Image-iT FX (Invitrogen) for 3 hrs.
Sections were then incubated overnight at 4uC with primary
antibody in TBS, 10% horse serum, 0.1% triton X-100 (Ndi1: 1/
300, TH: 1/300; Calbiochem). The anti-Ndi1 protein antibody
was revealed with a specific horseradish peroxidase conjugated
goat-anti-rabbit IgG (1/1000; Calbiochem) and the TSA Plus
Fluorescein system kit (PerkinElmer). The TH antibody was
revealed with Alexa fluor 568 goat anti mouse IgG (Invitrogen).
The level of TH in the striatum was estimated by using DAB (3,39
Diaminobenzidine; Sigma) staining. The specific TH antibody was
revealed with biotinylated secondary antibody and the ABC Elite
kit (Vector Laboratories). For the evaluation of NADH dehydro-
genase activity, brains were snap frozen and sliced into 30 mm
sections. The sections were then stained for 5 min at 37uC with a
solution containing 2 mg/ml nitro blue tetrazolium, 0.5 mM
NADH in 50 mM Tris-Cl, pH 7.6. The slices were washed twice
with TBS and destained with increasing concentrations of acetone
solutions (30%, 60%, 90%). The slices were dried and mounted
with Permount (Fisher).
Chemical analysis For the detection of rotenone in plasma,
200 ml of blood was harvested from the tail vein every week and the
plasma was kept frozen at280uC until use. Rotenone was extracted
from the plasma with 1 volume of dichloromethane (Sigma) for
15 minutes. After centrifugation the organic phase was evaporated
by Speedvac (Savant) for 5 min. These steps were repeated twice.
The pellet was dissolved in 30 ml of acetonitrile and samples of 15 ml
were analyzed on a C18 column (Waters Spherisorb 5 mm ODS2,
4.56150mm) at 214 nm. The mobile phase was composed of 70%
methanol in H2O and the flow rate was set at 1 ml/min. The
retention time of the rotenone peak was around 10.5 min.
For the detection of dopamine and its metabolites, the brains
were quickly collected, dissected and flash frozen on dry ice. The
right and left striata were isolated and weighed. Each sample was
homogenized in ice-cold 0.2 M perchloric acid (0.5ml of acid per
100 mg of wet tissue) using sonication. The homogenate was kept
on ice for 30 min and centrifuged at 20,000 g, for 15 min at 4uC.
The supernatant was analyzed on an Eicompak SC-30DS column
(36100 mm). The mobile phase was composed of 80 mM citrate-
acetate buffer (pH 3.5) containing 176 mg/l sodium octane
sulfonate, 4 mg/l EDTA and 20% (v/v) methanol. The signal
was detected through an electrochemical detector (EPC-500) set at
+750 mv (Eicom) coupled to a Power Chrom data processor
(Eicom). The flow rate was set at 0.4 ml/min. The amount of
dopamine at day 30 or day 60 didn’t show significant difference
and, therefore, the values were compiled into one histogram.
Behavioral testing The rotational behavior of rats was
measured by placing the animal into a round shape basket of
48 cm diameter over which a camcorder was mounted. The rats
were placed in the basket 15 minutes before they were injected
subcutaneously with 1.5 mg/kg apomorphine hydrochloride
(Sigma, Saint Louis, MO). The number of clockwise and
counter-clockwise turns and the speed of each animal were
monitored for 30 min, and the percentage of completely
lateralized animals per group was evaluated.
RESULTS
Evaluation of the rotenone rat model
A few methods are available to administer rotenone in rats. For
example, intravenous infusion via minipump [20] or intraperito-
NDI1 as a Therapeutic Agent
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neal injection [24] may be used. Our preliminary experiments
conducted with an intraperitoneal injection of rotenone, emulsified
in oil, turned out to exert noxious effects; the rats presented liver
necrosis and large weight loss (unpublished data). Subcutaneous
delivery of rotenone, on the other hand, was reported to be more
efficient in altering selectively the dopaminergic cells [22]. To
eliminate toxic effects derived from the materials used for
injections such as organic solvents, we carried out subcutaneous
injections of biodegradable microspheres containing rotenone, a
method originally adopted by Huang et al. [25]. After the
injection, we monitored the concentration of rotenone in the
plasma. As shown in Figure 1A, there was an initial increase in the
rotenone concentration during the first 2 weeks which was
followed by a gradual decrease. The rotenone concentration
remained above 1 mM throughout the period of our experiments
(60 days) presumably due to a slow and constant release of
rotenone from the polymer undergoing disintegration in the
animal body [26]. The rats lost about 2% of their body weight
during the first 15 days after the injection which coincided with an
increase in the rotenone concentration in the plasma, but there
was no further loss throughout the rest of the period (data not
shown). After 30 or 60 days of rotenone exposure, we examined
the brain for the extent and nature of the damage to the nigral
neurons. One of the features of PD is formation of filamentous
amyloid deposits, Lewy bodies. Such cytoplasmic aggregations
were observed in rotenone rat models of PD [22,27]. We
performed immunohistochemical staining of brain sections using
an antibody against a-synuclein or ubiquitin and detected Lewy-
body like inclusions in SN neurons of all the rats that were exposed
to rotenone (Figure 1B). Furthermore, Nissl staining of the brain
sections revealed a substantial decrease in the number of viable
neurons in the SN of rotenone-treated animals (see below). The
SN neurons of the rotenone-treated rats also exhibited extensive
staining with antibody against 8-oxo-dG, indicating oxidative
modification of DNA (Figure 1C). The oxidative damage was
observed in both mitochondrial and nuclear DNA.
Unilateral delivery of the NDI1 gene to the rat SN
and the effects of rotenone treatment
Using the rotenone rat model of PD, we carried out the
experiments that allow evaluation of capability and efficiency of
the Ndi1 protein as a therapeutic agent. We have previously
reported that the Ndi1 protein was functionally expressed in the
rat SN following a stereotaxic injection of recombinant AAV
carrying the NDI1 gene [16]. However, the level of the Ndi1
protein expression was variable and, therefore, not most suitable
for our aims. In an attempt to achieve a consistently high level and
a wider area of the Ndi1 protein expression in the SN, we selected
AAV serotype 5 [28] which was reported to deliver the transgene
in the SN more efficiently than AAV serotype 2 that was used in
our previous experiments [16]. The injection point was set at
0.4 mm above the SN in order to avoid any physical damage to
the dopaminergic pathway during the surgery. In all animals
tested, a single, unilateral injection of the viral particles resulted in
the expression of the Ndi1 protein in the entire SN spanning
1.8 mm sagittally. The wide distribution of the Ndi1 protein in the
SN dopaminergic neurons was evident in a coronal section of the
brain double-stained with antibodies to the Ndi1 protein and TH
(Figure S1, A and B). It was also confirmed that the Ndi1 protein
was localized to mitochondria (Figure S1, C–E) just as we reported
earlier using cultured cells of various origins [14,15,29] as well as
in rodents [16,18]. Near perfect colocalization of the Ndi1 protein
and mitochondria was most clearly visualized in a 3D image of an
SN neuron constructed from a series of confocal images of a brain
section double-stained for the Ndi1 protein and the a-subunit of
F1-ATPase (Movie S1). The level of TH and the amount of
dopamine were not affected by the Ndi1 protein expression. The
expressed Ndi1 protein was enzymatically active as seen in dense
staining derived from NADH dehydrogenase activity in the SN on
the injected side (Figure 2A).
We subjected the rats unilaterally expressing the Ndi1 protein to
rotenone exposure. The NADH dehydrogenase activity derived
from the Ndi1 protein was not affected by rotenone in agreement
with insensitivity of the enzyme to this chemical (Figure 2A).
Rotenone intoxication caused approximately 45% decrease in the
TH level of the SN that did not receive the NDI1 gene but almost no
effect on the SN expressing the Ndi1 protein (Figure 2B and 2C). In
fact, there was a good correlation between the presence of the Ndi1
protein and the TH staining as can be seen in Figure 2B in which
profiles of the staining intensity across the SN region are compared.
It should also be noted that the presence of the Ndi1 protein did not
cause any change in the TH level in the SN. The SN projects to all
areas of the striatum. In PD, severe neurodegeneration of the striatal
innervation derived from the SN neurons is observed. Therefore, we
examined the level of TH in the striatum by histochemical staining of
coronal brain sections (Figure S2). Statistical analysis of the images
indicated that rotenone exposure led to approximately 50% decrease
of TH on the contralateral striatum and that no discernible effect was
observed on the ipsilateral striatum as expected (Figure 2D) in good
agreement with the loss of TH in the SN.
As described above, rotenone exposure resulted in the
appearance of cytoplasmic aggregations. This Lewy-body like
structure seems to form less frequently, on the ipsilateral side, in
the group of rats that were injected with the NDI1 gene. However,
Figure 1. Characterization of the rotenone rat model. Rats received a
subcutaneous injection of microspheres encapsulating rotenone. A:
Concentration of rotenone in the plasma was determined on an HPLC
system from 200 ml of blood samples drawn from the tail vein from 4
rats every week for 60 days. Values are given with standard deviation
(SD). B: Rat brain coronal sections at the level of SN were subjected to
immunohistochemical staining with antibody against a-synuclein or
ubiquitin. Left panel, Lewy body-like cytoplasmic inclusions in SN
neurons (arrows). Scale bar is 10 mm. Right panels, images at a higher
magnification. C: The rat SN sections were stained with antibody
specific for 8-oxo-dG. Oxidatively modified DNA appeared in green.
Nuclei were stained in blue with DAPI. The image shows the damage to
both mitochondrial DNA (left arrow) and nuclear DNA (right arrow) in
SN neurons. Scale bar is 15 mm.
doi:10.1371/journal.pone.0001433.g001
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the total number of such inclusions was too small to obtain
statistically reliable data. Neuronal cell death is another key
observation in the rotenone rat model of PD. Approximately 50%
of the SN neurons died in our rotenone model (Figure 3A).
Comparison of the number of SN neurons between the injection
side and the opposite side clearly showed that the Ndi1 protein
expression prevented neuronal cell death in rotenone-treated
animals. The preferential death of the nigrostriatal neurons under
rotenone exposure may result from the synergic effect of ROS
production by complex I inhibition and the presence of dopamine
by way of production of oxyradicals and reactive intermediates
[30,31]. Our earlier experiments using rat PC12 cells demonstrat-
ed that the Ndi1 protein impedes the production of ROS triggered
by complex I inhibition presumably by taking over electron
transfer activity from endogenous complex I [17,29,32]. To
examine whether the Ndi1 protein can exert the same ROS-
reducing effect in vivo, we assessed the extent of oxidative DNA
modifications in the SN neurons. Again, the data from the Ndi1-
Figure 2. Expression of the Ndi1 protein in the rat SN and its effect on the TH levels in the SN and striatum after rotenone exposure. Rats
received a unilateral injection of recombinant AAV carrying the NDI1 gene targeted at the right SN. Control rats were injected with PBS. After the
expression of the Ndi1 protein has been established, microspheres containing rotenone were injected subcutaneously. For control, microspheres
with PBS were used. Thirty or 60 days later, brains were collected for analysis. A: After 30 days of rotenone exposure, brain sections at the level of SN
were stained for the NADH dehydrogenase (diaphorase) activity. The right SN that received the NDI1 gene showed high NADH dehydrogenase as
revealed by dense staining in both rotenone-treated (b) and PBS-treated (a) group. Non-NDI1 control rats did not exhibit discernible staining (c and
d). B: Brain sections from the same groups of rats as A were double-stained for TH (red) and the Ndi1 protein (green). The staining intensities across
the right SN (NDI1 injection side) and the left SN are plotted in arbitrary units below each set of the images. Each picture displays a representative
section of an animal from each group. C: Rats expressing the Ndi1 protein (NDI1) and non-NDI1 control group (Ctl) were treated with rotenone (Rot)
for 60 days and immunohistochemical staining for TH staining were carried out as in B. The fluorescence images of the brain sections were collected
and the staining intensity of TH from the left and the right SN was statistically analyzed (student T-test) using ImageJ [39]. Note that the right SN
received the NDI1 injection. The number of sections used was; Ctl (n = 6), Ctl+Rot (n = 9), NDI1 (n = 18) and NDI1+Rot (n = 18). Images in each group
were collected from evenly spaced sections that cover the entire SN in which the presence of the Ndi1 protein was detected. Error bars represent
standard deviation. D: Levels of TH staining in the left and right striatum from the same four groups of rats as in C are compared. The right striatum is
ipsilateral to the SN expressing the Ndi1 protein. Representative images of DAB staining of TH are given in Figure S2. The number of sections used for
analysis was; Ctl (n = 6), Ctl+Rot (n = 9), NDI1 (n = 9) and NDI1+Rot (n = 18). Error bars represent standard deviation.
doi:10.1371/journal.pone.0001433.g002
NDI1 as a Therapeutic Agent
PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1433
expressing SN exhibited almost no effect by rotenone whereas the
opposite side underwent the same degree of damage as non-Ndi1
controls (Figure 3B).
Dopamine levels in the striatum after rotenone
exposure and effect of expressing the Ndi1 protein
A decrease in dopamine content is associated with PD symptoms
and measurement of dopamine is commonly used for assessment
of neurodegeneration. In our rat model, the dopamine level in the
striatum of animals exposed to rotenone was decreased by 45% of
the control group (Figure 4). In the group that received the NDI1
gene in the SN unilaterally, the striatum contralateral to the SN of
the injection side lost dopamine to about the same extent as the
rotenone group without the NDI1 gene. The ipsilateral striatum,
however, retained the same concentration of dopamine as the non-
rotenone group. These results demonstrate that the Ndi1 protein
expression in the SN protected the nigrostriatal pathway in the
rotenone-administered rats.
Evaluation of the behavior of rats
In our rotenone model, the rats were seemingly active in
movement throughout the period of the experiments. We
measured the speed of movement of each animal by counting
Figure 3. Prevention of rotenone-induced neuronal cell death and oxidative damage by expression of the Ndi1 protein. Rats were treated with
the NDI1 gene and rotenone and brain sections were prepared and processed for immunohistochemical staining as described in Figure 2. A: Sections
were subjected to Nissl staining and representative images are displayed (upper panel). The number of viable neurons was compared between the
left and right SN by counting Nissl-positive cells in a given area of the SN (lower panel). The number of sections used for analysis was; control (2
animals, 3 sections), control+rotenone (5 animals, 12 sections) and NDI1+rotenone (9 animals, 9 sections). In each group, images were collected from
the sections with the matching anterior-posterior position and, when multiple sections were used in a given animal, they were separated by at least
30 mm to eliminate possible span of neuron cell bodies over multiple sections. B: Sections were stained for 8-oxo-dG to evaluate oxidative damage to
DNA (upper panel). The SN neurons that are positively stained were counted (lower panel). The number of sections used for analysis was; control (2
animals, 3 sections), control+rotenone (3 animals, 5 sections) and NDI1+rotenone (3 animals, 6 sections). Selection of the sections was done as
described in A. Statistic analysis was done using student T-test. Error bars represent standard deviation.
doi:10.1371/journal.pone.0001433.g003
Figure 4. Reduction of striatal dopamine by rotenone exposure and
its retention by expression of the Ndi1 protein. Procedures for the
NDI1 gene injection and rotenone exposure were the same as those
described in Figure 2. The striatal portions of unfixed brains were
dissected and homogenized. Samples were analyzed for dopamine
contents on an HPLC system coupled with an electrochemical detector.
The dopamine contents were determined for the left and right
hemisphere from the four groups, Ctl (n = 3), Ctl+Rot (n = 8), NDI1
(n = 3) and NDI1+Rot (n = 11). n = number of animals. All values are
presented with standard deviation.
doi:10.1371/journal.pone.0001433.g004
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the number of full turns per minute after an apomorphine
injection. The rotenone treatment slowed down the animals only
slightly but with a statistically significant difference (Figure 5A). A
similar slowdown was observed in the animals expressing the Ndi1
protein. It should be noted that we have deliberately chosen a
unilateral delivery of the NDI1 gene to achieve unequivocal
assessment of the consequences of the target gene expression by
comparing the two sides in the same animal. The impact on the
overall movement may be rather insignificant. However, this
unilateral treatment made it possible to carry out behavioral tests
involving turning preferences. A difference in the integrity between
the right and the left side of the dopaminergic pathways should lead
to an asymmetric behavior. Individual animals placed in a container
were monitored for their lateralization after an apomorphine
injection (Movie S2). Because the direction of rotation induced by
apomorphine seems to be dependent on multiple factors, we decided
to count the number of animals exhibiting 100% lateralized rotation
irrespective of the direction (for review see [33]). As illustrated in
Figure 5B, in the groups of rats that were not exposed to rotenone, a
small difference was noticed between the NDI1 group and the non-
NDI1 control group. However, this difference was not statistically
significant (p=0.242, student T-test). In the animals bearing the
Ndi1 protein in the SN, rotenone boosted the lateralized turning
significantly. The preferential turning of the NDI1 group of rats
completely agrees with the histochemical and biochemical analyses
described above.
DISCUSSION
The concept of complementing mammalian complex I with the
alternative NADH dehydrogenase was first tested in a variety of
cultured cells in our group [15,29,34] and, more recently, in other
laboratories [35,36]. The cell lines employed ranged from normal
cells of different origins such as kidney cells, fibroblasts and
neurons to complex I-deficient cells derived from patients or
cybrid cells. In all cases, the results were positive and the Ndi1
protein seems to be fully functional as a member of the host
respiratory chain and can restore NADH oxidation to complex I-
impaired cells. The first attempt to take this effort to the next step
of demonstrating it in live animals was quite successful. The Ndi1
protein expressed in the SN of mouse brain was able to
compensate for loss of complex I in dopaminergic neurons in
MPTP-exposed mice [18]. The initial success prompted us to
carry out the in vivo study using animals in a more detailed and
well-defined manner. Advancement in this direction required
improvement in at least two points.
First, we needed an efficient and reproducible method of
expression of the Ndi1 protein in the rat brain. It is known that
choice of the AAV serotype contributes to better expression of a
therapeutic gene and more selective expression in terms of tissue
specificity. Serotype 5 used in the present study turned out to be
quite suitable for targeting dopaminergic neurons in the rat SN. The
level and the spread of the Ndi1 protein in the SN remained
unchanged for at least 5 months while our experiments were
conducted. Second, we were able to establish a rat animal model of
PD in which to carry out all the biochemical and behavioral
experiments. The model follows in principle the chronic exposure of
rotenone to cause PD-like neurodegeneration in combination with
use of biodegradable polymers as the delivery tool of the chemical.
The animals under our procedure suffered only a minimal loss of
body weight throughout the period of the experiment and sustained
strength to allow behavioral testing. Another point that should be
noted regarding the current method is that we observe neuropath-
ological deficiencies in .80% of the animals tested. This number is
much higher than the previous model in which only 33–48% of the
rats developed striatal lesions [20,37]. A possible reason for the less
variability of rotenone effectiveness in the current study may be that
we used older (4 to 5 month-old) rats compared to the earlier studies
(,2 month-old). It should be pointed out that the data presented in
this study came from all animals used without excluding any.
Furthermore, the current rat model mimics human PD better than
our own mouse model [18] in several aspects such as death of SN
neurons and formation of Lewy body-like aggregations.
It is most obvious that the role of the Ndi1 protein as a
replacement of malfunctioning complex I is to offer a shuttle from
NADH to the downstream respiratory chain. However, there is an
important consequence to securing an alternative route for NADH
oxidation. That is prevention of overproduction of ROS by complex
I. We reported earlier that, in mitochondria isolated from PC12 cells
expressing the Ndi1 protein, ROS generation from complex I was
significantly less compared to that of mitochondria from control cells
[17]. This phenomenon is explained by the observation that the
NADH concentration of the mitochondria carrying the Ndi1 protein
remains low even when complex I is blocked [23] and that the
resulting high redox potential in the matrix does not allow ROS
formation by complex I [38]. It is well understood that ROS is a key
factor in the mechanism of cell death in PD. We indeed
demonstrated oxidative damage in the SN neurons in our rat
model, and such damage was not observed in the Ndi1-expressing
SN. It is conceivable that the Ndi1 protein in vivo is capable of
keeping the NADH level low enough just as in cultured cells [23].
In addition to harmful ROS generation, cellular ATP levels
might be involved in cell death caused by complex I defects.
Whether this is the major event is still debatable because, for
example, rotenone exposure does not seem to make any noticeable
change in the ATP level [32]. Regardless, it has been reported that
in cultured striatal neurons the Ndi1 protein sustains cellular ATP
even in the presence of a complex I inhibitor [35]. Furthermore,
we showed using PC12 cells that rotenone-induced loss of
mitochondrial membrane potential is prevented by the presence
of the Ndi1 protein [23].
The present study demonstrates, for the first time, that the yeast
Ndi1 protein protects the nigrostriatal pathway in a chronic
animal model of PD. Although the detailed mechanism of
protection has yet to be fully understood, the successful action
Figure 5. Behavioral tests of rotenone-exposed rats. Rotenone
exposure was carried out as described in Figure 2. Each rat was placed
in a round bucket after apomorphine administration and the movement
was video-taped for 30 min. Data were analyzed for the four groups; Ctl
(n = 3), Ctl+Rot (n = 14), NDI1 (n = 5) and NDI1+Rot (n = 20). n = number
of animals. A: Speed of movement of rats was calculated as the number
of full turns per minute. B: The number of rats exhibiting fully lateralized
turning in either direction was counted. Histograms represent
percentage of animals turning only in one direction. (*: p,0.05; **:
p,0.01). All values are presented with standard deviation.
doi:10.1371/journal.pone.0001433.g005
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exerted by the Ndi1 protein in the animal model that closely
mimics the pathophysiology of the disease is one critical step
forward toward the goal of retarding PD by a novel strategy.
SUPPORTING INFORMATION
Figure S1 Expression of the Ndi1 protein in dopaminergic
neurons of the substantia nigra (SN) of rat brain and its
localization to mitochondria. Recombinant adeno-associated virus
(serotype 5) carrying the NDI1 gene was stereotaxically injected to
the right SN. Coronal sections at the level of SN were subjected to
immunohistochemical staining. (A, B) Double-staining of a section
with antibody against Ndi1 (A) and tyrosine hydroxylase (TH) (B)
showing the expressed Ndi1 throughout SN neurons. Scale bar is
500 mm. (C–E) Confocal microscopy images of a SN neuron
double-stained with antibody to Ndi1 (C) and the a subunit of F1-
ATPase (D). Localization of Ndi1 to mitochondria is clearly seen
in the merged image (E). Scale bar is 8 mm.
Found at: doi:10.1371/journal.pone.0001433.s001 (2.72 MB TIF)
Figure S2 Representative images of immunohistochemical
staining of coronal sections at the level of striatum with antibody
against TH. The staining intensity for TH from four groups of rats
was statistically analyzed and the results were presented in
Figure 2C.
Found at: doi:10.1371/journal.pone.0001433.s002 (4.46 MB TIF)
Movie S1 3D images of a SN neuron double-stained with
antibody against Ndi1 (green) and the a subunit of F1-ATPase
(red). Immunohistochemical staining was carried out as described
in Figures S1 C and D, and successive confocal images were
collected along the Z-axis. 3D reconstruction of the cell was done
for each color from the stacked images using OsiriX. The resulting
movies were edited using Cinelerra to add a merged image and to
rotate them in a synchronized manner.
Found at: doi:10.1371/journal.pone.0001433.s003 (1.92 MB
MOV)
Movie S2 Rotenone-treated rats were monitored for lateralized
movement after apomorphine administration. Each rat was placed
in a bucket and video-taped for 30 min. The first section of the
movie is a non-NDI1 control rat and the second section is a rat
that received the NDI1 gene on the right SN. The movie is played
at 46 acceleration.
Found at: doi:10.1371/journal.pone.0001433.s004 (0.77 MB
MOV)
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